.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKesson
Queensland Health
McKinsey
Teva
Cerilliant
Harvard Business School
Express Scripts
Cantor Fitzgerald

Generated: July 28, 2017

DrugPatentWatch Database Preview

IRESSA Drug Profile

« Back to Dashboard

What is the patent landscape for Iressa, and what generic Iressa alternatives are available?

Iressa is a drug marketed by Astrazeneca Pharms and Astrazeneca and is included in two NDAs. There is one patent protecting this drug.

This drug has forty-five patent family members in thirty-five countries.

The generic ingredient in IRESSA is gefitinib. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gefitinib profile page.

Summary for Tradename: IRESSA

Patents:1
Applicants:2
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list105
Clinical Trials: see list223
Patent Applications: see list5,903
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:IRESSA at DailyMed

Pharmacology for Tradename: IRESSA

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms
IRESSA
gefitinib
TABLET;ORAL206995-001Jul 13, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Astrazeneca
IRESSA
gefitinib
TABLET;ORAL021399-001May 5, 2003DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
IRESSA
gefitinib
TABLET;ORAL206995-001Jul 13, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
IRESSA
gefitinib
TABLET;ORAL206995-001Jul 13, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: IRESSA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca
IRESSA
gefitinib
TABLET;ORAL021399-001May 5, 2003► Subscribe► Subscribe
Astrazeneca Pharms
IRESSA
gefitinib
TABLET;ORAL206995-001Jul 13, 2015► Subscribe► Subscribe
Astrazeneca
IRESSA
gefitinib
TABLET;ORAL021399-001May 5, 2003► Subscribe► Subscribe
Astrazeneca
IRESSA
gefitinib
TABLET;ORAL021399-001May 5, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: IRESSA

Country Document Number Estimated Expiration
Egypt24134► Subscribe
European Patent Office0823900► Subscribe
Bulgaria62730► Subscribe
China1182421► Subscribe
Taiwan436486► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: IRESSA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009009,C0823900Lithuania► SubscribePRODUCT NAME: GEFITINIBUM; REGISTRATION NO/DATE: EU/1/09/526/001 20090624
C/GB09/059United Kingdom► SubscribePRODUCT NAME: GEFITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 56154 20040302; UK EU/1/09/526/001 20090624
7Finland► Subscribe
2009009Lithuania► SubscribePRODUCT NAME: GEFITINIBUM; REGISTRATION NO/DATE: EU/1/09/526/001 20090624
2009 00051Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Fuji
Farmers Insurance
Teva
Citi
Covington
Federal Trade Commission
UBS
Cantor Fitzgerald
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot